ceruletide and Kidney-Diseases

Topics: Adult; Aged; Biliary Tract Diseases; Ceruletide; Clinical Trials as Topic; Colic; Female; Humans; Kidney Diseases; Male; Middle Aged; Random Allocation

A randomized controlled study has been carried out in order to check the activity of caerulein in the treatment of biliary and renal colic. In 88% out of 107 patients caerulein, 1 ng/kg IV, relieved biliary colic and had no side effects. To elucidate the mechanism of action of the peptide, 22 cholecystectomized patients, showing a dilation of the common bile duct (CBD), were submitted to caerulein treatment under echo-control. Reduction of CBD caliber was noticed when the dilatation was due to functional obstruction, whereas an organic obstruction of the terminal tract of CBD was found in the non-responding patients. Caerulein appears to be an effective agent in relieving biliary colic through a relaxation of Oddi's sphincter, and may be used in ultrasound differential diagnostics of terminal bile duct obstruction. Caerulein, 75 ng/kg intramuscularly, relieved renal colic in 75% of the examined patients; it is suggested that the effect of caerulein in this syndrome is due to central analgesic action.

Topics: Adolescent; Aged; Biliary Tract Diseases; Ceruletide; Colic; Double-Blind Method; Female; Humans; Kidney Diseases; Male; Middle Aged

The analgesic effect of ceruletide in biliary and renal colic was evaluated by a randomized, double-blind study in 82 patients. Ceruletide was compared with pentazocine, a well-established analgetic agent. Rapid and effective analgesia was obtained by intramuscular injection of ceruletide 0.5 micrograms/kg in 56 patients with biliary colic. The analgesic effect of ceruletide compared well with pentazocine 0.5 mg/kg im, and was associated with remarkably fewer side effects. In 26 patients with renal colic, ceruletide was significantly inferior to pentazocine. These data support the recommendation of ceruletide as a first-choice analgetic agent for biliary colic.

Topics: Adult; Biliary Tract Diseases; Ceruletide; Clinical Trials as Topic; Colic; Double-Blind Method; Female; Humans; Kidney Diseases; Male; Middle Aged; Pentazocine; Random Allocation; Time Factors